The latest avapritinib and ripretinib are effective and selective TKIs, which have been approved both internationally and in China for the treatment of PDGFRA 18 exon mutation and fourth‐line metastatic gastrointestinal stromal tumors, respectively. Here, PDGFRA is linked to gastrointestinal stromal tumor.